Nonmyeloablative alternative donor transplants

Current Opinion in Oncology

Volumn 15, Issue 2, 2003, Pages 121-126

  Luznik, Leo ^a   O'Donnell, Paul V ^b   Fuchs, Ephraim J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FLUDARABINE; HLA ANTIGEN; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY;

ALLOGRAFT; ANTINEOPLASTIC ACTIVITY; BONE MARROW TRANSPLANTATION; CHIMERA; CONDITIONING; FOLLOW UP; GENOTYPE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; LIVING DONOR; LYMPHOCYTE DEPLETION; MAJOR HISTOCOMPATIBILITY COMPLEX; MORTALITY; NONHUMAN; NONMYELOABLATIVE STEM CELL TRANSPLANTATION; OUTCOMES RESEARCH; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; RADIATION DOSE; REVIEW; SIBLING; TECHNIQUE; TREATMENT FAILURE; WHOLE BODY RADIATION;

AGE FACTORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY TESTING; HUMANS; NEOPLASMS; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0242500985     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200303000-00001     Document Type: Review

References (36)

1. Beatty PG, Clift RA, Mickelson EM, et al.: Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985, 313:765-71.
2. Anasetti C, Amos D, Beatty PG, et al.: Effect of HLA compatibility on engraftment of bone marrow transplants in patients with leukemia or lymphoma. N Engl J Med 1989, 320:197-204.
3. Anasetti C, Beatty PG, Storb R, et al.: Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 1990, 29:79-91.
4. Petersdorf EW, Mickelson EM, Anasetti C, et al.: Effect of HLA mismatches on the outcome of hematopoietic transplants. Curr Opin Immunol 1999, 11:521-6.
5. Davies SM, Kollman C, Anasetti C, et al.: Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood 2000, 96:4096-102.
6. Anasetti C, Petersdorf EW, Martin PJ, et al.: Trends in transplantation of hematopoietic stem cells from unrelated donors. Curr Opin Hematol 2001, 8:337-41.
7. Klingemann HG, Storb R, Fefer A, et al.: Bone marrow transplantation in patients aged 45 years and older. Blood 1986, 67:770-6.
8. Khouri IF, Keating M, Korbling M, et al.: Transplant-lite: induction of graft-versus-malignancy using fludarabine- based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998, 16:2817-24.
9. Childs R, Clave E, Contentin N, et al.: Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: full donor T-cell chimerism precedes alloimmune responses. Blood 1999, 94:3234-41.
10. Slavin S, Nagler A, Naparstek E, et al.: Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood 1998, 91:756-63.
11. McSweeney PA, Niederwieser D, Shizuru JA, et al.: Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001, 97:3390-400.
12. Storb R, Yu C, Wagner JL, et al.: Stable mixed hematopoietic chimerism in DLA-identical littermate dogs given sublethal total body irradiation before and pharmacological immunosuppression after marrow transplantation. Blood 1997, 89:3048-54.
13. McSweeney PA, Storb R: Mixed chimerism: preclinical studies and clinical applications. Biol Blood Marrow Transplant 1999, 5:192-203.
14. Niederwieser D, Maris M, Shizuru JA, et al.: Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematologic diseases. Blood 2002 (in press). This is the largest study using alternative donors after nonmyeloabrative allografting using pretransplant fludarabine, low dose TBI, and postgrafting immunosuppression with CSA/MMF. See also [15•].
15. Maris MB, Niederwieser D, Sandmaier BM, et al.: Nonmyeloabrative hematopoietic stem cell transplants (NM-HSCT) using 10 HLA antigen matched unrerated donors (URDs) for patients with advanced hematologic malignancies [abstract 275]. Blood 2002,100:75a. This is the largest series of patients transplanted using alternative donors and a recent update of reference 14.
16. Nagler A, Aker M, Or R, et al.: Low-intensity conditioning is sufficient to ensure engraftment in matched unrelated bone marrow transplantation. Exp Hematol 2001, 29:362-370. This study utilizes a reduced conditioning regimen consisting of busulfan, frudarabine, and ATG. Very young patient population.
17. Bornhauser M, Thiede C, Platzbecker U, et al.: Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients. Clin Cancer Res 2001, 7:2254-2262. Another study utilizing reduced conditioning with busulfan, fludarabine, and ATG. Some of the patients received CD34+ selected grafts.
18. Giralt S, Thall PF, Khouri I, et al.: Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood 2001, 97:631-637. Reduced conditioning with fludarabine and melphalan is adequate for engraftment of HLA-matched sibling donors and MUDs. High incidence of GVHD is reported.
19. Chakraverty R, Peggs K, Chopra R, et al.: Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen. Blood 2002, 99:1071-1078. Addition of CAMPATH-1 to reduced conditioning with fludarabine and melphalan decreases incidence of GVHD.
20. Sharabi Y, Sachs DH: Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J Exp Med 1989, 169:493-502.
21. Wekerle T, Sykes M: Mixed chimerism as an approach for the induction of transplantation tolerance. Transplantation 1999, 68:459-467.
22. Sykes M, Sheard MA, Sachs DH: Graft-versus-host-related immunosuppression is induced in mixed chimeras by alloresponses against either host or donor lymphohematopoietic cells. J Exp Med 1988, 168:2391-2396.
23. Pelot MR, Pearson DA, Swenson K, et al.: Lymphohematopoietic graft-vs.-host reactions can be induced without graft-vs.-host disease in murine mixed chimeras established with a cyclophosphamide-based nonmyeloablative conditioning regimen. Biol Blood Marrow Transplant 1999, 5:133-143.
24. Sykes M, Preffer F, McAfee S, et al.: Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 1999, 353:1755-1759.
25. Spitzer TR: Nonmyeloablative allogeneic stem cell transplant strategies and the role of mixed chimerism. Oncologist 2000, 5:215-223.
26. Mayumi H, Umesue M, Nomoto K: Cyclophosphamide-induced immunological tolerance: an overview. Immunobiology 1996, 195:129-139.
27. Colson YL, Li H, Boggs SS, et al.: Durable mixed allogeneic chimerism and tolerance by a nonlethal radiation-based cytoreductive approach. J Immunol 1996, 157:2820-2829.
28. Luznik L, Jalla S, Engstrom LW, et al.: Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood 2001, 98:3456-3464.
29. O'Donnell PV, Luznik L, Jones RJ, et al.: Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002, 8:377-386. This study demonstrates feasibility of nonmyeloablative allografting using PMRD.
30. Battiwalla M, Barrett J: Allogeneic transplantation using non-myeloablative transplant regimens. Best Pract Res Clin Haematol 2001, 14:701-722.
31. Feinstein L, Sandmaier B, Maloney D, et al.: Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect. Ann NY Acad Sci 2001, 938:328-337; discussion 337-339.
32. Aizawa S, Sado T: Graft-versus-leukemia effect in MHC-compatible and -incompatible allogeneic bone marrow transplantation of radiation-induced, leukemia-bearing mice. Transplantation 1991, 52:885-889.
33. Johnson BD, Becket EE, Truitt RL: Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets. Biol Blood Marrow Transplant 1999, 5:123-132.
34. Ruggeri L, Capanni M, Urbani E, et al.: Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
35. Yu X, Carpenter P, Anasetti C: Advances in transplantation tolerance. Lancet 2001, 357:1959-1963.
36. Wells AD, Li XC, Li Y, et al.: Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat Med 1999, 5:1303-1307.